{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T15:08:00Z","timestamp":1791472080396,"version":"4.3.4"},"reference-count":35,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,9]],"date-time":"2024-01-09T00:00:00Z","timestamp":1704758400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.clml.2023.11.001","type":"journal-article","created":{"date-parts":[[2023,11,14]],"date-time":"2023-11-14T19:18:36Z","timestamp":1699989516000},"page":"194-202","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Teclistamab Improves Patient-Reported Symptoms and Health-Related Quality of Life in Relapsed or Refractory Multiple Myeloma: Results From the Phase II MajesTEC-1 Study"],"prefix":"10.1016","volume":"24","author":[{"given":"Thomas G.","family":"Martin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Moreau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saad Z.","family":"Usmani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfred","family":"Garfall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda-Victoria","family":"Mateos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jes\u00fas F.","family":"San-Miguel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert","family":"Oriol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajay K.","family":"Nooka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2534-9239","authenticated-orcid":false,"given":"Laura","family":"Rosinol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajai","family":"Chari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lionel","family":"Karlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amrita","family":"Krishnan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nizar","family":"Bahlis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rakesh","family":"Popat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Britta","family":"Besemer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joaqu\u00edn","family":"Mart\u00ednez-L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Delforge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle","family":"Trancucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lixia","family":"Pei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Kobos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Fastenau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharine S.","family":"Gries","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7445-2603","authenticated-orcid":false,"given":"Niels W.C.J.","family":"van de Donk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.clml.2023.11.001_bib0001","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1186\/s12885-020-6637-6","article-title":"Physical function in patients newly diagnosed with multiple myeloma: a Danish cohort study","volume":"20","author":"Larsen","year":"2020","journal-title":"BMC Cancer"},{"issue":"2","key":"10.1016\/j.clml.2023.11.001_bib0002","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1111\/j.1600-0609.2009.01250.x","article-title":"Health related quality of life in a nationally representative sample of haematological patients","volume":"83","author":"Johnsen","year":"2009","journal-title":"Eur J Haematol"},{"issue":"4","key":"10.1016\/j.clml.2023.11.001_bib0003","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1111\/j.1600-0609.2012.01831.x","article-title":"Health-related quality of life and disease-specific complaints among multiple myeloma patients up to 10 yr after diagnosis: results from a population-based study using the PROFILES registry","volume":"89","author":"Mols","year":"2012","journal-title":"Eur J Haematol"},{"issue":"3","key":"10.1016\/j.clml.2023.11.001_bib0004","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.annonc.2020.11.014","article-title":"Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up(dagger)","volume":"32","author":"Dimopoulos","year":"2021","journal-title":"Ann Oncol"},{"issue":"14","key":"10.1016\/j.clml.2023.11.001_bib0005","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1200\/JCO.18.02096","article-title":"Treatment of multiple myeloma: ASCO and CCO Joint Clinical Practice Guideline","volume":"37","author":"Mikhael","year":"2019","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.clml.2023.11.001_bib0006","doi-asserted-by":"crossref","first-page":"2266","DOI":"10.1038\/s41375-019-0435-7","article-title":"Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy","volume":"33","author":"Gandhi","year":"2019","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.clml.2023.11.001_bib0007","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.clml.2019.10.002","article-title":"Treatment journeys of patients with newly diagnosed multiple myeloma (NDMM): results from the Connect MM Registry","volume":"20","author":"Jagannath","year":"2020","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"1","key":"10.1016\/j.clml.2023.11.001_bib0008","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/leu.2011.196","article-title":"Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study","volume":"26","author":"Kumar","year":"2012","journal-title":"Leukemia"},{"issue":"11","key":"10.1016\/j.clml.2023.11.001_bib0009","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1038\/leu.2017.138","article-title":"Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study","volume":"31","author":"Kumar","year":"2017","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/j.clml.2023.11.001_bib0010","doi-asserted-by":"crossref","first-page":"e160","DOI":"10.1016\/j.clml.2020.10.002","article-title":"Real-world evaluation of health-related quality of life in patients with multiple myeloma from Germany","volume":"21","author":"Engelhardt","year":"2021","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"1","key":"10.1016\/j.clml.2023.11.001_bib0011","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1007\/s00520-020-05493-y","article-title":"Symptom burden and its functional impact in patients with \"symptomatic\" relapsed or refractory multiple myeloma","volume":"29","author":"Kamal","year":"2021","journal-title":"Support Care Cancer"},{"issue":"3","key":"10.1016\/j.clml.2023.11.001_bib0012","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1111\/bjh.17321","article-title":"Health-related quality of life maintained over time in patients with relapsed or refractory multiple myeloma treated with daratumumab in combination with bortezomib and dexamethasone: results from the phase III CASTOR trial","volume":"193","author":"Hungria","year":"2021","journal-title":"Br J Haematol"},{"issue":"18","key":"10.1016\/j.clml.2023.11.001_bib0013","doi-asserted-by":"crossref","first-page":"4538","DOI":"10.1182\/bloodadvances.2020002393","article-title":"Teclistamab is an active T cell-redirecting bispecific antibody against B-cell maturation antigen for multiple myeloma","volume":"4","author":"Pillarisetti","year":"2020","journal-title":"Blood Adv"},{"issue":"10301","key":"10.1016\/j.clml.2023.11.001_bib0014","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/S0140-6736(21)01338-6","article-title":"Teclistamab, a B-cell maturation antigen\u2008\u00d7\u2008CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study","volume":"398","author":"Usmani","year":"2021","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.clml.2023.11.001_bib0015","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa2203478","article-title":"Teclistamab in relapsed or refractory multiple myeloma","volume":"387","author":"Moreau","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2023.11.001_bib0016","unstructured":"TECVAYLI [summary of product characteristics]. Janssen Biologics BV; 2022. Available at: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/tecvayli-epar-product-information_en.pdf. Accessed: September 1, 2023."},{"key":"10.1016\/j.clml.2023.11.001_bib0017","unstructured":"TECVAYLI [prescribing information]. Janssen Biotech, Inc; 2022. Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022?761291s000lbl.pdf. Accessed: September 1, 2023."},{"issue":"18","key":"10.1016\/j.clml.2023.11.001_bib0018","doi-asserted-by":"crossref","first-page":"4691","DOI":"10.1182\/blood-2010-10-299487","article-title":"Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1","volume":"117","author":"Rajkumar","year":"2011","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.clml.2023.11.001_bib0019","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","article-title":"The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology","volume":"85","author":"Aaronson","year":"1993","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.clml.2023.11.001_bib0020","series-title":"EORTC QLQ-C30 Scoring Manual (3rd edition)","author":"Fayers","year":"2001"},{"issue":"3","key":"10.1016\/j.clml.2023.11.001_bib0021","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1046\/j.1365-2141.1996.352889.x","article-title":"Measurement of health-related quality of life in multiple myeloma. Nordic Myeloma Study Group","volume":"92","author":"Wisloff","year":"1996","journal-title":"Br J Haematol"},{"issue":"5","key":"10.1016\/j.clml.2023.11.001_bib0022","doi-asserted-by":"crossref","first-page":"784","DOI":"10.3324\/haematol.2012.074534","article-title":"Lenalidomide, melphalan, and prednisone, followed by lenalidomide maintenance, improves health-related quality of life in newly diagnosed multiple myeloma patients aged 65 years or older: results of a randomized phase III trial","volume":"98","author":"Dimopoulos","year":"2013","journal-title":"Haematologica"},{"issue":"12","key":"10.1016\/j.clml.2023.11.001_bib0023","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1007\/s00277-018-3469-4","article-title":"Impact of elotuzumab treatment on pain and health-related quality of life in patients with relapsed or refractory multiple myeloma: results from the ELOQUENT-2 study","volume":"97","author":"Cella","year":"2018","journal-title":"Ann Hematol"},{"issue":"10","key":"10.1016\/j.clml.2023.11.001_bib0024","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1007\/s11136-011-9903-x","article-title":"Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L)","volume":"20","author":"Herdman","year":"2011","journal-title":"Qual Life Res"},{"issue":"8","key":"10.1016\/j.clml.2023.11.001_bib0025","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol"},{"issue":"13","key":"10.1016\/j.clml.2023.11.001_bib0026","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1016\/j.ejca.2008.05.008","article-title":"Quality, interpretation and presentation of European Organisation for Research and Treatment of Cancer quality of life questionnaire core 30 data in randomised controlled trials","volume":"44","author":"Cocks","year":"2008","journal-title":"Eur J Cancer"},{"issue":"2","key":"10.1016\/j.clml.2023.11.001_bib0027","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1177\/1758834010395342","article-title":"Health-related quality of life and cancer clinical trials","volume":"3","author":"Osoba","year":"2011","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.clml.2023.11.001_bib0028","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/1477-7525-5-70","article-title":"Estimation of minimally important differences in EQ-5D utility and VAS scores in cancer","volume":"5","author":"Pickard","year":"2007","journal-title":"Health Qual Life Outcomes"},{"issue":"1","key":"10.1016\/j.clml.2023.11.001_bib0029","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1186\/s12885-021-08453-9","article-title":"Quality of life analyses in patients with multiple myeloma: results from the Selinexor (KPT-330) Treatment of Refractory Myeloma (STORM) phase 2b study","volume":"21","author":"Tremblay","year":"2021","journal-title":"BMC Cancer"},{"issue":"4","key":"10.1016\/j.clml.2023.11.001_bib0030","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1182\/bloodadvances.2021005913","article-title":"Health-related quality of life with idecabtagene vicleucel in relapsed and refractory multiple myeloma","volume":"6","author":"Delforge","year":"2022","journal-title":"Blood Adv"},{"issue":"3","key":"10.1016\/j.clml.2023.11.001_bib0031","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1111\/bjh.17887","article-title":"Patient-reported outcomes in relapsed\/refractory multiple myeloma treated with melflufen plus dexamethasone: analyses from the Phase II HORIZON study","volume":"196","author":"Larocca","year":"2022","journal-title":"Br J Haematol"},{"issue":"2","key":"10.1016\/j.clml.2023.11.001_bib0032","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/s00520-013-1991-4","article-title":"Effect of general symptom level, specific adverse events, treatment patterns, and patient characteristics on health-related quality of life in patients with multiple myeloma: results of a European, multicenter cohort study","volume":"22","author":"Jordan","year":"2014","journal-title":"Support Care Cancer"},{"issue":"1","key":"10.1016\/j.clml.2023.11.001_bib0033","doi-asserted-by":"crossref","first-page":"e1429","DOI":"10.1002\/cnr2.1429","article-title":"Patient-reported pain severity and health-related quality of life in patients with multiple myeloma in real world clinical practice","volume":"5","author":"Ludwig","year":"2022","journal-title":"Cancer Rep (Hoboken)"},{"issue":"7","key":"10.1016\/j.clml.2023.11.001_bib0034","doi-asserted-by":"crossref","first-page":"5859","DOI":"10.1007\/s00520-022-06979-7","article-title":"Patient perspectives on symptoms, health-related quality of life, and treatment experience associated with relapsed\/refractory multiple myeloma","volume":"30","author":"Nathwani","year":"2022","journal-title":"Support Care Cancer"},{"issue":"8","key":"10.1016\/j.clml.2023.11.001_bib0035","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.6004\/jnccn.2020.7561","article-title":"Symptom burden, perceived control, and quality of life among patients living with multiple myeloma","volume":"18","author":"Zaleta","year":"2020","journal-title":"J Natl Compr Canc Netw"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265023021717?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265023021717?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T10:48:58Z","timestamp":1709290138000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265023021717"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":35,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["S2152265023021717"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2023.11.001","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Teclistamab Improves Patient-Reported Symptoms and Health-Related Quality of Life in Relapsed or Refractory Multiple Myeloma: Results From the Phase II MajesTEC-1 Study","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2023.11.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}